AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – Here’s What Happened

Shares of AIM ImmunoTech Inc. (NYSE:AIM) traded down 8.1% during mid-day trading on Monday . The company traded as low as $0.18 and last traded at $0.19. 1,000,809 shares traded hands during trading, an increase of 26% from the average session volume of 791,607 shares. The stock had previously closed at $0.20.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AIM shares. Ascendiant Capital Markets dropped their price target on AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Tuesday, December 10th. Maxim Group cut their target price on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, October 22nd.

AIM ImmunoTech Price Performance

The stock has a market capitalization of $9.09 million, a price-to-earnings ratio of -0.30 and a beta of -0.29. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a 50 day moving average price of $0.21 and a 200-day moving average price of $0.26.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).